Erika P. Hamilton, MD

Articles

Dr. Hamilton on the Utility of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

October 12th 2021

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Dr. Hamilton on the Potential Integration of Novel SERDs in ER+/HER2- Breast Cancer

October 4th 2021

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers

March 22nd 2021

Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.

Dr. Hamilton on the Rationale Behind OP-1250 in HR+ Metastatic Breast Cancer

January 21st 2021

Erika P. Hamilton, MD, discusses the rationale behind examining OP-1250 in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Hamilton on the Mechanism of Action of OP-1250 in HR+/HER2- Metastatic Breast Cancer

December 12th 2020

Erika P. Hamilton, MD, discusses the mechanism of action of OP-1250 in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr. Hamilton on the Exploration of CDK4/6 Inhibitors in Breast Cancer

October 6th 2020

Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.

Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic Tumors

October 1st 2020

Erika P. Hamilton, MD, highlights initial findings from the ​ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer

September 23rd 2020

Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

Dr. Hamilton on the Complex Treatment Algorithm for HER2+ Breast Cancer

September 8th 2020

Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.

Dr. Hamilton on Recent Advances in HER2+ Breast Cancer

August 31st 2020

Erika P. Hamilton, MD, discusses the roles of fam-trastuzumab deruxtecan-nxki and tucatinib in HER2-positive breast cancer.

Dr. Hamilton on the Promise of Tucatinib in HER2+ Breast Cancer Brain Metastases

August 18th 2020

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

August 18th 2020

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Dr. Hamilton on the Evolution of Treatment in HER2+ Breast Cancer

May 8th 2020

Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Dr. Hamilton on the FDA Approval of Tucatinib in HER2+ Breast Cancer

April 17th 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the FDA approval of tucatinib (Tukysa) in HER2-positive breast cancer.

Dr. Hamilton on Using pCR to Classify Risk in HER2+ Breast Cancer

April 9th 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the use of pathologic complete response (pCR) as a way to classify risk status in HER2-positive breast cancer.

Dr. Hamilton on the Results of the KATHERINE Trial in HER2+ Breast Cancer

February 14th 2020

Erika P. Hamilton, MD, discusses the superiority of ado-trastuzumab emtansine (T-DM1; Kadcyla) in the phase III KATHERINE study.

Dr. Hamilton on the DESTINY-Breast01 Trial in HER2+ Breast Cancer

February 6th 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the phase II DESTINY-Breast01 trial in advanced HER2-positive breast cancer.

Dr. Hamilton on the HER2CLIMB Trial in Metastatic HER2+ Breast Cancer

January 10th 2020

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the phase II HER2CLIMB trial in metastatic HER2-positive breast cancer.

Dr. Hamilton on the KATHERINE Trial in HER2+ Breast Cancer

December 3rd 2019

Erika P. Hamilton, MD, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.

Dr. Hamilton on the Impact of Biosimilars in Oncology

November 12th 2019

Erika P. Hamilton, MD, discusses the impact of biosimilars in oncology.